Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Tuvusertib

Stage Phase 2

Sponsor GEINO

Modality small molecule

Class ATR inhibitor (ATRX-altered)

Target ATR

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07417761

Efficacy of Tuvusertib in Recurrent IDH Mutant Astrocytoma With ATRX Mutation, a Phase II Prospective Trial.

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

TUVASTRAT

Registry NCT07417761

Phase Phase 2

Status Recruiting

Enrollment 56

Start 2025-12-19

Primary completion 2028-09

Study completion 2028-09

Catalyst Primary completion. 09.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.